» Articles » PMID: 36647452

A Scoring System Based on Laboratory Parameters and Clinical Features to Predict Unfavorable Treatment Outcomes in Multidrug- and Rifampicin-Resistant Tuberculosis Patients

Overview
Publisher Dove Medical Press
Date 2023 Jan 17
PMID 36647452
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The growth of antibiotic resistance to Mycobacterium TB represents a major barrier to the goal of "Ending the global TB epidemics". This study aimed to develop and validate a simple clinical scoring system to predict the unfavorable treatment outcomes (UTO) in multidrug- and rifampicin-resistant tuberculosis (MDR/RR-TB) patients.

Methods: A total of 333 MDR/RR-TB patients were recruited retrospectively. The clinical, radiological and laboratory features were gathered and selected by lasso regression. These variables with area under the receiver operating characteristic curve (AUC)>0.6 were subsequently submitted to multivariate logistic analysis. The binomial logistic model was used for establishing a scoring system based on the nomogram at the training set (N = 241). Then, another independent set was used to validate the scoring system (N = 92).

Results: The new scoring system consists of age (8 points), education level (10 points), bronchiectasis (4 points), red blood cell distribution width-coefficient of variation (RDW-CV) (7 points), international normalized ratio (INR) (7 points), albumin to globulin ratio (AGR) (5 points), and C-reactive protein to prealbumin ratio (CPR) (6 points). The scoring system identifying UTO has a discriminatory power of 0.887 (95% CI=0.835-0.939) in the training set, and 0.805 (95% CI=0.714-0.896) in the validation set. In addition, the scoring system is used exclusively to predict the death of MDR/RR-TB and has shown excellent performance in both training and validation sets, with AUC of 0.930 (95% CI=0.872-0.989) and 0.872 (95% CI=0.778-0.967), respectively.

Conclusion: This novel scoring system based on seven accessible predictors has exhibited good predictive performance in predicting UTO, especially in predicting death risk.

Citing Articles

Development and validation of a nomogram predicting multidrug-resistant tuberculosis risk in East China.

He F, Wang S, Wang H, Ding X, Huang P, Fan X PeerJ. 2025; 13:e19112.

PMID: 40034676 PMC: 11874934. DOI: 10.7717/peerj.19112.


An early scoring system to predict mechanical ventilation for botulism: a single-center-based study.

An Y, Zheng T, Dong Y, Wu Y, Gong Y, Ma Y World J Emerg Med. 2024; 15(5):365-371.

PMID: 39290599 PMC: 11402867. DOI: 10.5847/wjem.j.1920-8642.2024.067.


Nutritional Indices Predict All Cause Mortality in Patients with Multi-/Rifampicin-Drug Resistant Tuberculosis.

Hu S, Guo J, Chen Z, Gong F, Yu Q Infect Drug Resist. 2024; 17:3253-3263.

PMID: 39104459 PMC: 11298562. DOI: 10.2147/IDR.S457146.


Construction and Validation of a Nomogram to Identify the Risk of Cavitation in Pulmonary Tuberculosis.

Song M, Zhang M, Han J, Fu W Infect Drug Resist. 2024; 17:2803-2813.

PMID: 38989008 PMC: 11233379. DOI: 10.2147/IDR.S459330.

References
1.
Karimi A, Shobeiri P, Kulasinghe A, Rezaei N . Novel Systemic Inflammation Markers to Predict COVID-19 Prognosis. Front Immunol. 2021; 12:741061. PMC: 8569430. DOI: 10.3389/fimmu.2021.741061. View

2.
Arroyo L, Ramos A, Yamamura M, Berra T, Alves L, Belchior A . Predictive model of unfavorable outcomes for multidrug-resistant tuberculosis. Rev Saude Publica. 2019; 53:77. PMC: 6752648. DOI: 10.11606/s1518-8787.2019053001151. View

3.
Dicker A, Lonergan M, Keir H, Smith A, Pollock J, Finch S . The sputum microbiome and clinical outcomes in patients with bronchiectasis: a prospective observational study. Lancet Respir Med. 2021; 9(8):885-896. DOI: 10.1016/S2213-2600(20)30557-9. View

4.
Gunther G, Lange C, Alexandru S, Altet N, Avsar K, Bang D . Treatment Outcomes in Multidrug-Resistant Tuberculosis. N Engl J Med. 2016; 375(11):1103-5. DOI: 10.1056/NEJMc1603274. View

5.
Yu Q, Yan J, Tian S, Weng W, Luo H, Wei G . A scoring system developed from a nomogram to differentiate active pulmonary tuberculosis from inactive pulmonary tuberculosis. Front Cell Infect Microbiol. 2022; 12:947954. PMC: 9478038. DOI: 10.3389/fcimb.2022.947954. View